Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SLN124 in Healthy Volunteers
NCT04559971Phase 1Completed
- Sponsor
- Silence Therapeutics
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SLN124 in beta thalassemia, myelodysplastic syndrome (MDS) and polycythemia vera (PV) (4 arms), sponsored by Silence Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at 8 weeks. Started Sep 2020; status: completed.
02
Drugs
SLN124
03
Conditions
beta thalassemiamyelodysplastic syndrome (MDS)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04559971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559971.